Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.
The authors measured CSF concentrations of corticotropin-releasing hormone (CRH) and arginine vasopressin in nine depressed patients before and after fluoxetine treatment. They found significant decreases in CSF CRH, CSF arginine vasopressin, and Hamilton depression ratings. Thus, the therapeutic effect of this serotonin-uptake inhibitor may be related to diminution of these arousal-promoting neuropeptides.
De Bellis
M D
MD
Clinical Neuroendocrinology Branch, NIMH, Bethesda, MD 20892.
Gold
P W
PW
Geracioti
T D
TD
Listwak
S J
SJ
Kling
M A
MA
D000328:Adult; D001127:Arginine Vasopressin / Q000134:cerebrospinal fluid*; D003346:Corticotropin-Releasing Hormone / Q000134:cerebrospinal fluid*; D003864:Depression, Chemical; D003866:Depressive Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales
D005473:Fluoxetine; D001127:Arginine Vasopressin; D003346:Corticotropin-Releasing Hormone